Companies /Healthcare

Aktis Oncology

NASDAQ: AKTS Biotechnology
$16.15
▼ $0.25 (−1.52%) today
Markets closed · 4:31am ET

AKTS at a Glance

Valuation
Market cap
$915.1M
Profitability
Revenue (TTM)
$12.4M
EPS (TTM)
$-1.80
Price
52-week range
$14 – $34
Street target
$35.88

Headquartered in Boston, MA Fiscal year ends December NASDAQ: AKTS aktisoncology.com

About Aktis Oncology

Aktis Oncology, Inc. (NASDAQ: AKTS) is a clinical-stage oncology company developing targeted radiopharmaceuticals intended for large patient populations, including tumor types not addressed by existing radiopharmaceutical platforms.

Its proprietary, isotope-agnostic miniprotein radioconjugate platform is designed to deliver radioisotopes such as actinium-225 selectively to tumors. The design aims for high tumor penetration, internalization and retention in cancer cells, with rapid clearance from normal tissue. The platform also allows imaging-based verification of target engagement before therapeutic dosing.

The company has two clinical-stage programs:
- **AKY-1189:** targets Nectin-4 and is in the Phase 1b NECTINIUM-2 trial in urothelial cancer, breast cancer and other Nectin-4-expressing tumors.
- **AKY-2519:** targets B7-H3 and is in the Phase 1b BActinium-1 trial in metastatic castration-resistant prostate cancer and the BActinium-2 trial in non-small cell lung cancer and other B7-H3 tumors.

Two early-stage programs are approaching development-candidate nomination.

Aktis earns collaboration revenue from a discovery partnership with Eli Lilly and Company, which applies the miniprotein platform to novel radioconjugates outside Aktis' proprietary pipeline. For clinical supply, it uses a hybrid model of contract manufacturers, isotope suppliers and an in-house GMP facility at 17 Drydock.

The company completed its IPO in January 2026. Updated

AKTS Coverage

Frequently Asked Questions

What does Aktis Oncology do?

Aktis Oncology, Inc. (NASDAQ: AKTS) is a clinical-stage oncology company developing targeted radiopharmaceuticals intended for large patient populations, including tumor types not addressed by existing radiopharmaceutical platforms.

What is the AKTS stock price target?

The Wall Street consensus 12-month price target for AKTS is $35.88.